From YMB.
Something to talk about all good talking points.
“At the very least, we are getting an update at the scheduled quarterly call which will be announced soon. We should be receiving this press release on the time and date of the call no later than the first week of July. It has been very quiet since the last quarterly call in early April. FDA probably had more inquiries pertaining to the risk/benefit analysis or the new trial protocol.Medical leave is typically for 12 weeks if applying the FMLA standard. If applied to Cyrus, this puts his return at worst case by mid-August if he is not looking for external employment (as the shorts would imply)I was checking Pacer on any court updates from the NP/SEC+DOJ case and the Courter vs. Cytodyn case. No activity on either matter in over a month. No updates on clinicaltrials.gov either. No 8k on the interim CFO or strategic advisor. Is it possible that CYDY decides not to continue pursuing the lift of the HIV partial clinical hold and focuses on the development of a phase 2B NASH trial that also encompasses a safety arm to the trial with enrollment beginning in Quarter 3 with the blessing of the FDA? There is already some safety data from the phase 2A exploratory trial so it would not technically be starting from scratch on this indication. I would assume if this were the case ...despite the fact that CYDY can't sell on the open market, there will be an ask to approve more authorized shares in the very near future... since there is hardly any cash left at this point. Thoughts?”
Something to talk about all good talking points.
“At the very least, we are getting an update at the scheduled quarterly call which will be announced soon. We should be receiving this press release on the time and date of the call no later than the first week of July. It has been very quiet since the last quarterly call in early April. FDA probably had more inquiries pertaining to the risk/benefit analysis or the new trial protocol.Medical leave is typically for 12 weeks if applying the FMLA standard. If applied to Cyrus, this puts his return at worst case by mid-August if he is not looking for external employment (as the shorts would imply)I was checking Pacer on any court updates from the NP/SEC+DOJ case and the Courter vs. Cytodyn case. No activity on either matter in over a month. No updates on clinicaltrials.gov either. No 8k on the interim CFO or strategic advisor. Is it possible that CYDY decides not to continue pursuing the lift of the HIV partial clinical hold and focuses on the development of a phase 2B NASH trial that also encompasses a safety arm to the trial with enrollment beginning in Quarter 3 with the blessing of the FDA? There is already some safety data from the phase 2A exploratory trial so it would not technically be starting from scratch on this indication. I would assume if this were the case ...despite the fact that CYDY can't sell on the open market, there will be an ask to approve more authorized shares in the very near future... since there is hardly any cash left at this point. Thoughts?”
